Tumor mutational burden is associated with poor outcomes in diffuse glioma

BACKGROUND: Tumor mutational burden (TMB) is a potential biomarker for immune checkpoint therapy and prognosis. The impact of TMB on clinical outcomes and the correlation coefficient between exome sequencing and targeted sequencing in glioma have not yet been explored. METHODS: Somatic mutations in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lihong, Ge, Jia, Lan, Yang, Shi, Yu, Luo, Ying, Tan, Yuhuan, Liang, Mei, Deng, Song, Zhang, Xia, Wang, Wenying, Tan, Yaoyao, Xu, Yuanyuan, Luo, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069200/
https://www.ncbi.nlm.nih.gov/pubmed/32164609
http://dx.doi.org/10.1186/s12885-020-6658-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069200/
https://www.ncbi.nlm.nih.gov/pubmed/32164609
http://dx.doi.org/10.1186/s12885-020-6658-1

Ejemplares similares